WO2019184248A1 - 检测力生长因子、其e肽的金刚烷化学发光试剂盒、制法 - Google Patents

检测力生长因子、其e肽的金刚烷化学发光试剂盒、制法 Download PDF

Info

Publication number
WO2019184248A1
WO2019184248A1 PCT/CN2018/104101 CN2018104101W WO2019184248A1 WO 2019184248 A1 WO2019184248 A1 WO 2019184248A1 CN 2018104101 W CN2018104101 W CN 2018104101W WO 2019184248 A1 WO2019184248 A1 WO 2019184248A1
Authority
WO
WIPO (PCT)
Prior art keywords
mgf
antibody
solution
ct24e
buffer
Prior art date
Application number
PCT/CN2018/104101
Other languages
English (en)
French (fr)
Inventor
李大军
蔡淑娟
徐霞飞
涂策
张金林
Original Assignee
苏州长光华医生物医学工程有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州长光华医生物医学工程有限公司 filed Critical 苏州长光华医生物医学工程有限公司
Publication of WO2019184248A1 publication Critical patent/WO2019184248A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Definitions

  • the present invention relates to an adamantane chemiluminescence kit for detecting a force growth factor and an E-peptide thereof, and a preparation method thereof, and belongs to the technical field of immunoassay.
  • Force growth factor was first discovered in stretch-stimulated skeletal muscle and is an important allosteric variant produced by the selective splicing of insulin-like growth factor-I (IGF-I) gene under the induction of force stimulation. Splicing occurs at the site before exon 6 of the IGF-I gene, whereas in the region of exon 5, MGF inserts 49 bp and 52 bp, respectively, in humans and rodents, resulting in a frameshift mutation in translation of exon 6. A specific C-terminal 24-amino acid E peptide sequence (MGF-Ct24E) was generated.
  • MGF and MGF-Ct24E can activate muscle satellite cells, promote tissue regeneration, promote osteoblast proliferation, and play a role in stress stimulation and neuronal and muscle tissue responses to injury in osteoblasts or bone tissue, in response to mature motor neurons. Maintenance also plays an important role in promoting the proliferation and survival of a variety of cells. Other studies have found that MGF and MGF-Ct24 help to improve memory.
  • MGF can be modified by chemical modification of the C-terminus and/or N-terminus, such as PEGylation, LD-type amino acid conversion, glycosylation, sulfation, amidation, acetylation, etc., to increase the stability of MGF.
  • the modified MGF and MGF-Ct24E can be formulated into pharmaceutical preparations, such as aqueous and non-aqueous sterile injectable solutions, aqueous and non-aqueous sterile suspensions, which can be administered by skin, parenteral, intramuscular, subcutaneous or transdermal.
  • the drug is administered by direct injection into the blood or directly to the mucosal tissue for treating various diseases such as skeletal muscle disorders, myocardial disorders, and neurological disorders.
  • MGF and MGF-Ct24E can be applied to the field of tissue engineering, and bioactive biomimetic materials can be prepared by linking with modified polylactic acid materials in a suitable manner for bone regeneration and repair, vascular regeneration and the like.
  • MGF and MGF-Ct24E can be loaded onto the surface of the magnesium alloy in a suitable manner, and implanted in the body to release in time to stimulate the growth of osteoblasts to overcome the problems caused by insufficient stress.
  • MGF and MGF-Ct24E are so extensive. How to detect the presence of MGF and MGF-Ct24E when bone cells or bone tissue are damaged by stress or nerve or muscle tissue damage? How to monitor the metabolism of the preparation in the body to facilitate treatment/give
  • the drug program how to monitor the release rate of MGF and MGF-Ct24E in biomimetic materials, is an urgent problem to be solved.
  • only Western blotting is used to detect MGF and MGF-Ct24E, and the Western blotting detection is only qualitative analysis, which is not quantitative, and the speed is slow.
  • the technical problem to be solved by the present application is to provide a method for detecting a force growth factor and an E-peptide thereof, in order to solve the technical problem of a method or a kit for quantitatively detecting MGF and MGF-Ct24E in the prior art.
  • An adamantane chemiluminescence kit for detecting a force growth factor and an E-peptide thereof comprising: streptavidin-coupled magnetic particle working solution, biotin-labeled MGF and/or MGF-Ct24E antibody working solution, alkaline Phosphatase-labeled MGF and/or MGF-Ct24E antibody working solution containing 3-(2-helixadamantane)-4-methoxy-4-(3-phosphoryl)-phenyl-1,2-di a chemiluminescent substrate liquid of oxacyclohexane disodium salt, a cleaning solution.
  • the MGF and/or MGF-Ct24E antibody is a monoclonal antibody, a polyclonal antibody, a monoclonal antibody Fab fragment or a polyclonal antibody Fab fragment, preferably derived from a mouse, rabbit, or sheep.
  • the streptavidin-coupled magnetic microparticle working solution comprises a phosphate buffer solution having a pH of 6.8 to 7.6 and a concentration of 0.01 mol/L to 0.2 mol/L, a Tris buffer solution, a HEPES buffer solution, and a MOPSO.
  • the buffers containing 0.05 to 2% by weight of bovine serum albumin and/or casein, and 0.02 to 1% by weight of dodecyl polyethylene glycol ether ( Brij35) and/or polyethylene glycol to isooctylphenyl ether (Triton X-100) and/or polyoxyethylene sorbitan monolaurate (Tween 20) and/or lauryl polyoxyethylene ether ( Leveling plus O-20), 0.05 to 0.5% by weight of proclin 300 and/or sodium azide.
  • dodecyl polyethylene glycol ether Brij35
  • polyethylene glycol to isooctylphenyl ether Triton X-100
  • polyoxyethylene sorbitan monolaurate Tween 20
  • lauryl polyoxyethylene ether Leveling plus O-20
  • the biotin-labeled MGF and/or MGF-Ct24E antibody and the alkaline phosphatase-labeled MGF and/or MGF-Ct24E antibody working solution have a pH of 6.0-7.6 and a concentration of 0.01 mol/L to 0.2 mol.
  • the buffer contains 0.5 to 5 wt% of bovine serum albumin, 1 mg / L ⁇ 100 mg/L of murine IgG, 0.5 to 5 wt% of sodium chloride, 1-5 wt% of sucrose, 0.05 to 2 wt% of calf serum, 0.02 to 1 wt% of casein, 0.02 to 1 wt% of Brij35 and/or Triton X-100 and / or Tween 20 and / or flat plus O-20, 0.5-5mmol / L magnesium sulfate or magnesium chloride, 0.05-0.5mmol / L zinc chloride or zinc sulfate, 0.05 ⁇ 0.5wt% proclin 300 and / or sodium azide.
  • the adamantane chemiluminescence kit for detecting a force growth factor and/or its E peptide further comprises an MGF and/or MGF-Ct24E calibrator working solution and/or a quality control working fluid, the MGF and/or MGF-Ct24E calibrator and / or control working fluid from pH 6.0 ⁇ 7.6, concentration of 0.01mol / L ⁇ 0.2mol / L phosphate buffer, Tris buffer, HEPES buffer, MES buffer
  • the preparation comprises a bovine serum albumin in an amount of 0.5 to 5% by weight, 10 to 50% by weight of human serum, 0.5 to 3% by weight of sodium chloride, and 2 to 20% by weight of B. Glycol, 0.02 to 1 wt% Brij 35 and/or Triton X-100 and/or Tween 20 and/or plain plus O-20, 0.05 to 0.5 wt% proclin 300 and/or sodium azide.
  • the cleaning solution is a phosphate buffer solution or a Tris buffer solution having a pH of 6.8 to 7.6 and a concentration of 0.1 mol/L to 2 mol/L, and the buffer solution contains Triton in a mass percentage of 0.2 to 10% by weight.
  • the chemiluminescent substrate solution is 0.01 mol/L to 0.2 mol/L diethanolamine buffer or 2-amino-2-methyl-1-propanol buffer, and the buffer contains 0.01-0.05 wt. % of 3-(2-helixadamantane)-4-methoxy-4-(3-phosphonooxy)-phenyl-1,2-dioxetane disodium salt, 0.01-0.04% by weight 2,5-bis(5-tert-butyl-2-benzoxazolyl)thiophene, 0.5-5 mmol/L magnesium sulfate or magnesium chloride, 0.05-0.5 mmol/L zinc chloride or zinc sulfate, 0.02-1 wt. % Triton X-100 and/or Tween 20, 0.05-0.5 wt% proclin 300 and/or sodium azide.
  • the buffer contains 0.01-0.05 wt. % of 3-(2-helixadamantane)-4-methoxy-4-(3
  • the present invention also provides a method for preparing an adamantane chemiluminescence kit for detecting a force growth factor and an E peptide thereof, comprising: preparation of a streptavidin-coupled magnetic particle working solution, biotin-labeled MGF and/or Or preparation of MGF-Ct24E antibody working solution, preparation of alkaline phosphatase-labeled MGF and/or MGF-Ct24E antibody working solution, preparation of cleaning solution, preparation of chemiluminescent substrate solution, and dispensing of the above prepared reagent And assembly.
  • the biotin-labeled MGF and/or MGF-Ct24E antibody is prepared by: N-hydroxysuccinimide-activated biotin and MGF and/or MGF-Ct24E antibody according to 1:10-100 The molar ratio is rotated and mixed at 2-8 ° C or room temperature for 0.5-2 hours, and excess biotin is removed by dialysis to obtain biotin-labeled MGF and/or MGF-Ct24E antibody.
  • the alkaline phosphatase-labeled MGF and/or MGF-Ct24E antibody is prepared by:
  • the hydroformylated alkaline phosphatase and the MGF and/or MGF-Ct24E antibody are reacted in the reaction system at a pH of 9.0 to 10.7 at 2-8 ° C for 1-3 hours, and then mixed with NaBH 4 solution.
  • the reaction was carried out at 2-8 ° C for 20-40 minutes, and the mass ratio of the MGF and/or MGF-Ct24E antibody, NaBH 4 to alkaline phosphatase was 1:0.2:1-5, and finally the reaction solution was dialyzed.
  • the excess hydroformylated alkaline phosphatase and NaBH 4 are removed to obtain an alkaline phosphatase-labeled MGF and/or MGF-Ct24E antibody.
  • the present application provides an adamantane chemiluminescence kit for detecting a force growth factor and an E-peptide thereof, and a preparation method, wherein the luminescence system of the kit is alkaline phosphatase/3-(2-helixadamantane)-4- Chemiluminescence of methoxy-4-(3-phosphoryl)-phenyl-1,2-dioxetane disodium salt, using streptavidin-biotin signal amplification system, high sensitivity and linearity Wide range and good repeatability of test results, can achieve accurate quantification of force growth factor and / or its E peptide; especially the kit is used in fully automatic chemiluminescence system, loading, incubation, cleaning and detection steps Automated, avoiding the deviation of results caused by human operation and improving work efficiency.
  • the built-in standard curve to the test software only the test sample can be used to quantitatively detect the force growth factor and/or force growth factor E peptide in the sample, so that the detection Faster,
  • Example 1 Method for preparing chemiluminescence kit for detecting force growth factor and/or its E peptide
  • the streptavidin-coupled magnetic particle suspension was magnetically separated to remove the supernatant, and resuspended to a concentration of 0.5 mg/mL with a pH of 6.8 and a concentration of 0.1 mol/L in Tris buffer, the buffer containing The mass percentage was 0.5% by weight of bovine serum albumin, 0.05% by weight of Triton X-100, 0.05% proclin 300 and 0.05% sodium azide.
  • NHS-Biotin N-hydroxysuccinimide-activated biotin
  • the NHS-Biotin aqueous solution was added to the antibody, and the NHS-Biotin and the antibody were spin-mixed at a molar ratio of 1:50 at 2-8 ° C for 1 hour to obtain a biotin-labeled MGF antibody solution;
  • the biotin-labeled MGF antibody solution is transferred to a dialysis bag for dialysis, and the dialysate is changed every 3-4 hours, and replaced 3-4 times.
  • the biotin-labeled MGF antibody is collected into a centrifuge tube or a cryotube, and added. 1/10 volume of PBS-BSA buffer (0.01M, pH 7.0-7.6) containing 5wt% BSA, and then add glycerin after mixing.
  • the volume of glycerol added is the volume of the collected labeled antibody plus the volume of PBS-BSA buffer. After mixing, put it at ⁇ -15 °C for storage.
  • a Tris buffer having a pH of 7.5 and a concentration of 0.05 mol/L was prepared.
  • the buffer contained 2% by weight of bovine serum albumin, 0.1% by weight of casein, 60 mg/L of mouse IgG, and 1% by weight.
  • the solution was prepared with a biotin-labeled MGF antibody antibody working solution having an antibody concentration of 0.5 mg/L, and an alkaline phosphatase-labeled MGF antibody working solution having an antibody concentration of 0.25 mg/L.
  • HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
  • the buffer containing a mass percentage 1 wt% of bovine serum albumin, 20 wt% of human serum, 1 wt% of sodium chloride, 5 wt% of ethylene glycol, 0.1 wt% of Tween-20, 0.2 wt% of proclin 300; then, MGF was prepared using the buffer Calibrator and control solution working fluid, calibrator a total of 6 points, MGF concentration of 0pmol / L, 0.8pmol / L, 4pmol / L, 16pmol / L, 80pmol / L, 200pmol / L, quality control products The concentration of MGF was high, medium and low, and the concentrations of MGF were 4pmol/L, 16pmol/L and 80pmol/L, respectively.
  • Tris buffer having a pH of 7.5 and a concentration of 0.2 mol/L was prepared, and the buffer contained 1% by weight of Tween 20, 10% by weight of sodium chloride, and 10% by weight of proclin300.
  • a 0.2 mol/L 2-amino-2-methyl-1-propanol buffer was prepared as a substrate solution containing 0.05% by weight of 3-(2-helixadamantane)-4-methoxy- 4-(3-phosphonooxy)-phenyl-1,2-dioxacyclohexane disodium salt, 0.04% by weight of 2,5-bis(5-tert-butyl-2-benzoxazolyl) Thiophene, 1 mmol/L magnesium chloride, 0.1 mmol/L zinc chloride, 0.1 wt% Triton X-100, 0.1 wt% proclin 300.
  • the streptavidin-coupled magnetic particle suspension was magnetically separated to remove the supernatant, and resuspended to a concentration of 1 mg/mL with a pH of 6.8 and a concentration of 0.2 mol/L in HEPES buffer.
  • the buffer contained mass. The percentage is 2% by weight of bovine serum albumin, 0.02% by weight of Triton X-100, and 0.05% of sodium azide.
  • NHS-Biotin N-hydroxysuccinimide-activated biotin
  • the NHS-Biotin aqueous solution was added to the antibody, and the NHS-Biotin and the antibody were spin-mixed at a molar ratio of 1:100 at 2-8 ° C for 2 hours to obtain a biotin-labeled MGF antibody solution;
  • the biotin-labeled MGF antibody solution is transferred to a dialysis bag for dialysis, and the dialysate is changed every 3-4 hours, and replaced 3-4 times.
  • the biotin-labeled MGF antibody is collected into a centrifuge tube or a cryotube, and added. 1/10 volume of PBS-BSA buffer (0.01M, pH 7.0-7.6) containing 5wt% BSA, and then add glycerin after mixing.
  • the volume of glycerol added is the volume of the collected labeled antibody plus the volume of PBS-BSA buffer. After mixing, put it at ⁇ -15 °C for storage.
  • a phosphate buffer solution having a pH of 6.0 and a concentration of 0.2 mol/L was prepared, and the buffer contained 5 wt% of bovine serum albumin, 0.0.02 wt% of casein, and 1 mg/L of murine IgG.
  • the buffer was prepared at a concentration of 0.5 mg/L of biotin-labeled MGF antibody working solution, and at a concentration of 0.25 mg/L alkaline phosphatase-labeled MGF antibody working solution.
  • a N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES) buffer having a pH of 7.6 and a concentration of 0.2 mol/L, the buffer containing a mass percentage 5 wt% of bovine serum albumin, 10 wt% of human serum, 0.5 wt% of sodium chloride, 20 wt% of ethylene glycol, 0.02 wt% of Tween-20, 0.5 wt% of proclin 300; then formulated with the buffer MGF-Ct24E calibrator and quality control working fluid, calibrator working solution a total of 6 points, MGF-Ct24E concentration of 0pmol / L, 0.8pmol / L, 4pmol / L, 16pmol / L, 80pmol / L, 200pmol /L, the quality control products are divided into three high, medium and low concentrations, the concentration of MGF-Ct24E is 4pmol / L, 16pmol / L
  • a phosphate buffer having a pH of 7.6 and a concentration of 2 mol/L was prepared, and the buffer contained 10% by weight of Tween 20, 5% by weight of sodium chloride, and 15% by weight of proclin 300.
  • a 0.01 mol/L diethanolamine buffer was prepared as a substrate solution containing 0.01% by weight of 3-(2-helixadamantane)-4-methoxy-4-(3-phosphoryl)-benzene 1,2-dioxacyclohexane disodium salt, 0.02 wt% of 2,5-bis(5-tert-butyl-2-benzoxazolyl)thiophene, 5 mol/L of magnesium sulfate, 0.05 mol /L zinc sulfate, 0.02 wt% Tween 20, 0.05 wt% sodium azide.
  • Example 3 Method for preparing chemiluminescence kit for detecting force growth factor and/or its E peptide
  • the streptavidin-coupled magnetic particle suspension was magnetically separated to remove the supernatant, and resuspended to a concentration of 0.1 mg/mL with a phosphate buffer having a pH of 7.6 and a concentration of 0.01 mol/L. It contains 0.05% by weight of casein protein, 1% by weight of Brij35, and 0.5% of proclin 300.
  • NHS-Biotin N-hydroxysuccinimide-activated biotin
  • the NHS-Biotin aqueous solution was added to the MGF-Ct24E goat monoclonal antibody, and the NHS-Biotin and MGF-Ct24E goat monoclonal antibody were vortexed and mixed at a molar ratio of 1:10 at room temperature for 0.5 hour to obtain biotin-labeled MGF-Ct24E antibody solution;
  • a Tris buffer having a pH of 7.6 and a concentration of 0.01 mol/L was prepared, and the buffer contained 0.5% by weight of bovine serum albumin, 100 mg/L of mouse IgG, 0.5% by weight of sodium chloride, 5 wt% sucrose, 0.05 wt% calf serum, 0.02 wt% flat plus O-20, 0.5 mmol/L magnesium sulfate, 0.5 mmol/L zinc chloride, 0.5 wt% sodium azide;
  • the buffer was formulated with a biotinylated MGF-Ct24E antibody working solution at a concentration of 0.5 mg/L, and an alkaline phosphatase labeled MGF-Ct24E antibody working solution at a concentration of 0.25 mg/L.
  • a MES buffer having a pH of 6.8 and a concentration of 0.01 mol/L was prepared, and the buffer contained 0.5% by weight of bovine serum albumin, 1% by weight of casein, 50% by weight of human serum, and 3% by weight.
  • the concentration of MGF was 0pmol/L, 0.8pmol/L, 4pmol/L, 16pmol/L, 80pmol/L, 200pmol/L, and the quality control products were divided into three concentrations: high, medium and low, and the concentration of MGF was 4pmol/L. 16 pmol / L, 80 pmol / L.
  • a phosphate buffer solution having a pH of 6.8 and a concentration of 0.1 mol/L was prepared, and the buffer contained 0.2% by weight of Triton X-100, 20% by weight of sodium chloride, and 0.5% by weight of sodium azide. .
  • a 0.05 mol/L 2-amino-2-methyl-1-propanol buffer was prepared as a substrate solution containing 0.02% by weight of 3-(2-helixadamantane)-4-methoxy- 4-(3-phosphonooxy)-phenyl-1,2-dioxacyclohexane disodium salt, 0.01% by weight of 2,5-bis(5-tert-butyl-2-benzoxazolyl) Thiophene, 0.5 mmol/L magnesium sulfate, 0.5 mmol/L zinc chloride, 0.5 wt% Triton X-100, 0.5 wt% Tween 20, 0.25 wt% proclin 300, 0.25 wt% sodium azide.
  • Example 4 Method for detecting MGF and/or MGF-Ct24E using the kit of the present application
  • a fully automated chemiluminescence immunoassay analyzer access 2 was used as a detection instrument, and the kit was loaded onto the instrument for detection. The steps are as follows:
  • the magnetic composite suspension is placed in a magnetic field, and the cleaning solution is diluted 10-30 times, the magnetic composite is washed;
  • a chemiluminescent substrate liquid was successively injected into the washed magnetic composite to measure the photon intensity.
  • the S0 calibrator (0 pmol/L) was repeatedly measured 20 times by the detection method of Example 4, and the RLU values were: 2029, 2375, 2513, 2666, 2786, 2595, 2702, 2753, 2653.
  • the minimum detection limit obtained using the kit of Example 2 was 0.025 pmol/L
  • the minimum detection limit obtained using the kit of Example 3 was 0.037 pmol/L.
  • a high value calibrator of 80 pmol/L was added to a 0.8 pmol/L low value calibrator to recover the sample, the high value calibrator added and the volume of the low value calibrator added.
  • the ratio is 1:9.
  • the high-value calibrator, the low-value calibrator, and the recovered sample are repeatedly detected twice, and the corresponding RLU value is obtained, and the corresponding concentration value and concentration average are calculated.
  • the value, the test results are shown in Table 1, and the recovery rate R was calculated according to the following formula, and the result was 105.2%.
  • V 0 the volume of the low value calibrator
  • V the volume of the high value calibrator
  • the linear correlation coefficient obtained using the kit of Example 2 was 0.9992
  • the linear correlation coefficient obtained using the kit of Example 3 was 0.9995.
  • the test solution having the concentrations of 4 pmol/L, 16 pmol/L, and 80 pmol/L was repeatedly measured 10 times each time, and the corresponding RLU value was obtained and calculated.
  • Corresponding concentration value and concentration average And standard deviation (s), according to the formula The coefficient of variation was calculated.
  • the corresponding coefficients of variation for the working fluids of the three concentration levels were 3.5%, 3.9%, and 3.2%, respectively (see Table 3 for the results).
  • the coefficient of variation corresponding to the working fluid of the three control levels was 3.6%, 4.5%, and 5.1%, respectively, and three concentrations were obtained using the kit of Example 3.
  • the corresponding coefficients of variation for the horizontal control fluids were 3.3%, 4.5%, and 3.8%, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

一种检测力生长因子、其E肽的金刚烷化学发光试剂盒、制法，试剂盒包括：链霉亲和素偶联的磁性微粒工作液，生物素标记的MGF和/或MGF-Ct24E抗体工作液，碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液，MGF和MGF-Ct24E校准品和/或质控品工作液，含3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐的化学发光底物液，清洗液，试剂盒的发光体系为碱性磷酸酶/3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐化学发光，利用链霉亲和素-生物素信号放大系统，可以实现力生长因子和/或其E肽的定量。

Description

检测力生长因子、其E肽的金刚烷化学发光试剂盒、制法 技术领域
本申请涉及一种检测力生长因子、其E肽的金刚烷化学发光试剂盒、制法，属于免疫分析技术领域。
背景技术
力生长因子(MGF)最初在拉伸刺激的骨骼肌中被发现，是肌肉在力刺激诱导下，由胰岛素样生长因子-Ⅰ(IGF-Ⅰ)基因选择性剪接产生的重要变构体，选择剪接发生在IGF-Ⅰ基因外显子6之前的位点，而MGF在外显子5这一区域，人类和啮齿动物类分别插入了49bp和52bp，导致外显子6的翻译发生移码突变，产生特异的C端24个氨基酸的E肽序列(MGF-Ct24E)。
MGF及MGF-Ct24E能够激活肌肉卫星细胞，促进组织再生，促进成骨细胞增殖，在成骨细胞或骨组织对应力刺激以及神经、肌肉组织对损伤的响应中发挥作用，对成熟运动神经元的维持也有着重要作用，具有促进多种细胞增殖和存活的作用。还有研究发现，MGF及MGF-Ct24有助于改善记忆。
通过对C-末端和/或N-末端进行化学修饰，如聚乙二醇化、L-D型氨基酸转化、糖基化、硫酸化、酰胺化、乙酰化等方法修饰MGF，可增加MGF的稳定性，修饰后的MGF及MGF-Ct24E可制成药物制剂，如水性和非水性无菌注射液、水性和非水性无菌悬液，制剂可通过皮肤、肠胃外、肌肉、皮下或经皮肤等方式给药，或者通过直接注射到 血液中或直接施用至粘膜组织给药，用来治疗骨骼肌障碍、心肌障碍、神经障碍等多种疾病。
MGF及MGF-Ct24E可以应用到组织工程领域，通过合适的方式与改性的聚乳酸材料连接制备生物活性仿生材料，用于骨再生修复、血管再生修复等。另外，MGF及MGF-Ct24E可以通过合适的方式负载到镁合金表面，植入体内及时释放从而刺激成骨细胞的增长，来克服应力不足引起的问题。
MGF及MGF-Ct24E的应用如此广泛，如何检测骨细胞或骨组织受到应力刺激或神经、肌肉组织受到损伤时是否有MGF及MGF-Ct24E产生，如何监控制剂在体内代谢程度以便于制定治疗/给药方案，如何监测仿生材料中MGF及MGF-Ct24E的释放速度，这些都是需要迫切解决的问题。然而，现有技术中仅有蛋白质免疫印迹法检测MGF及MGF-Ct24E，而该蛋白质免疫印迹检测只是定性的分析，不能定量，且速度较慢，目前尚未有快速、准确地定量检测MGF及MGF-Ct24E的方法或试剂盒。
申请内容
本申请要解决的技术问题是：为解决现有技术中尚未有快速、准确地定量检测MGF及MGF-Ct24E的方法或试剂盒的技术问题，提供一种检测力生长因子、其E肽的金刚烷化学发光试剂盒、制法。
本申请解决其技术问题所采用的技术方案是：
一种检测力生长因子、其E肽的金刚烷化学发光试剂盒，包括：链霉亲和素偶联的磁性微粒工作液，生物素标记的MGF和/或 MGF-Ct24E抗体工作液，碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液，含3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐的化学发光底物液，清洗液。
优选地，所述MGF和/或MGF-Ct24E抗体为单克隆抗体、多克隆抗体、单克隆抗体Fab片段或多克隆抗体Fab片段，优选来源于鼠、兔、羊。
优选地，所述链霉亲和素偶联的磁性微粒工作液由pH为6.8～7.6，浓度为0.01mol/L～0.2mol/L的磷酸盐缓冲液、Tris缓冲液、HEPES缓冲液、MOPSO缓冲液中的一种配制而成，所述缓冲液含有质量百分含量为0.05～2wt％的牛血清白蛋白和/或酪蛋白、0.02～1wt％的十二烷基聚乙二醇醚(Brij35)和/或聚乙二醇对异辛基苯基醚(Triton X-100)和/或聚氧乙烯失水山梨醇单月桂酸酯(Tween 20)和/或月桂醇聚氧乙烯醚(平平加O-20)、0.05～0.5wt％的proclin 300和/或叠氮钠。
优选地，所述生物素标记的MGF和/或MGF-Ct24E抗体以及碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液由pH为6.0～7.6，浓度为0.01mol/L～0.2mol/L的磷酸盐缓冲液、Tris缓冲液、HEPES缓冲液、MOPSO缓冲液中的一种配制而成，所述缓冲液含有质量百分含量为0.5～5wt％的牛血清白蛋白、1mg/L～100mg/L的鼠IgG、0.5～5wt％的氯化钠、1～5wt％的蔗糖、0.05～2wt％的小牛血清、0.02～1wt％的酪蛋白、0.02～1wt％的Brij35和/或Triton X-100和/或Tween 20和/或平平加O-20、0.5-5mmol/L的硫酸镁或氯化镁、 0.05-0.5mmol/L的氯化锌或硫酸锌、0.05～0.5wt％的proclin 300和/或叠氮钠。
优选地，所述检测力生长因子和/或其E肽的金刚烷化学发光试剂盒还包括MGF和/或MGF-Ct24E校准品工作液和/或质控品工作液，所述MGF和/或MGF-Ct24E校准品和/或质控品工作液由pH为6.0～7.6，浓度为0.01mol/L～0.2mol/L的磷酸盐缓冲液、Tris缓冲液、HEPES缓冲液、MES缓冲液中的一种配制而成，所述缓冲液中含有质量百分含量为0.5～5wt％的牛血清白蛋白、10～50wt％的人血清、0.5～3wt％的氯化钠、2～20wt％的乙二醇、0.02～1wt％的Brij35和/或Triton X-100和/或Tween 20和/或平平加O-20、0.05～0.5wt％的proclin 300和/或叠氮钠。
优选地，所述清洗液为pH为6.8～7.6，浓度为0.1mol/L～2mol/L的磷酸盐缓冲液或Tris缓冲液，所述缓冲液含有质量百分含量为0.2～10wt％的Triton X-100和/或Tween 20、5～20wt％的氯化钠、0.5～15wt％的proclin 300和/或叠氮钠。
优选地，所述化学发光底物液为0.01mol/L-0.2mol/L二乙醇胺缓冲液或2-氨基-2-甲基-1-丙醇缓冲液，所述缓冲液含有0.01-0.05wt％的3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐、0.01-0.04wt％的2,5-双(5-叔丁基-2-苯并恶唑基)噻吩、0.5-5mmol/L的硫酸镁或氯化镁、0.05-0.5mmol/L的氯化锌或硫酸锌、0.02～1wt％的Triton X-100和/或Tween 20、0.05～0.5wt％的proclin 300和/或叠氮钠。
本申请还提供一种上述检测力生长因子、其E肽的金刚烷化学发光试剂盒的制法，包括：链霉亲和素偶联的磁性微粒工作液的制备，生物素标记的MGF和/或MGF-Ct24E抗体工作液的制备，碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液的制备，清洗液的配制，化学发光底物液的配制，将上述制备的试剂进行分装及组装。
优选地，所述生物素标记的MGF和/或MGF-Ct24E抗体的制备方法为：将N-羟基琥珀酰亚胺活化的生物素与MGF和/或MGF-Ct24E抗体按照1:10-100的摩尔比在2-8℃或室温条件下旋转混匀反应0.5-2小时，透析除去多余的生物素，得生物素标记的MGF和/或MGF-Ct24E抗体。
优选地，所述碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体的制备方法为：
于碱性磷酸酶水溶液中加入NaIO 4溶液，使碱性磷酸酶与NaIO 4按2-8mg:0.01-0.05mmol的比例在2-8℃下避光反应20-40分钟，透析除去多余的NaIO 4，得醛化的碱性磷酸酶；
将醛化的碱性磷酸酶与MGF和/或MGF-Ct24E抗体于PH为9.0-10.7的反应体系中，在2-8℃下避光反应1-3小时，再加NaBH 4溶液混匀，置于2-8℃下避光反应20-40分钟，所述MGF和/或MGF-Ct24E抗体、NaBH 4与碱性磷酸酶的质量比为1:0.2:1-5，最后将反应液透析除去多余醛化的碱性磷酸酶和NaBH 4，得碱性磷酸酶标记MGF和/或MGF-Ct24E抗体。
本申请的有益效果是：
本申请提供了一种检测力生长因子、其E肽的金刚烷化学发光试剂盒、制法，制备的试剂盒的发光体系为碱性磷酸酶/3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐化学发光，利用链霉亲和素-生物素信号放大系统，检测灵敏度高、线性范围宽，检测结果重复性好，可以实现力生长因子和/或其E肽的准确定量；尤其是将该试剂盒用于全自动化学发光系统，加样、孵育、清洗和检测等步骤均可实现自动化，避免了人为操作带来的结果偏差，提高了工作效率，通过内置标准曲线到测试软件，只需测试样本即可定量检测样本中力生长因子和/或力生长因子E肽，使检测更快速、更可靠、更稳定。
具体实施方式
现在对本申请作进一步详细的说明。
实施例1 检测力生长因子和/或其E肽的化学发光试剂盒的制法
1)链霉亲和素偶联的磁性微粒工作液的制备
将链霉亲和素偶联的磁微粒悬浮液，磁分离去除上清，用pH为6.8，浓度为0.1mol/L的Tris缓冲液重悬至浓度为0.5mg/mL，所述缓冲液含有质量百分含量为0.5wt％的牛血清白蛋白、0.05wt％的Triton X-100、0.05％proclin 300和0.05％叠氮钠。
2)生物素标记的MGF抗体的制备
取1mg MGF鼠单克隆抗体，加入适量PBS缓冲液(0.05M，pH7.0-7.6)调整抗体总浓度至1mg/ml，并加入透析袋中进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后将抗体转移至离心 管或冻存管内；
准确称取1mg N-羟基琥珀酰亚胺活化的生物素(NHS-Biotin)，加入适量水调整其浓度为2mg/ml，得NHS-Biotin水溶液；
将NHS-Biotin水溶液加入抗体中，使NHS-Biotin与抗体按照1:50的摩尔比在2-8℃旋转混匀反应1小时，得生物素标记的MGF抗体溶液；
将生物素标记的MGF抗体溶液转移至透析袋进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后收集生物素标记的MGF抗体至离心管或冻存管内，加入1/10体积含5wt％BSA的PBS-BSA缓冲液(0.01M，pH7.0-7.6)，混匀后再加入甘油，所加甘油体积为所收集标记抗体体积加PBS-BSA缓冲液的体积，混匀后置于≤-15℃保存备用。
3)碱性磷酸酶标记的MGF抗体的制备
取1mg MGF鼠单克隆抗体，加入适量CBS缓冲液(0.05M，pH8.0-9.6)调整抗体总浓度至1mg/ml，并加入透析袋中，进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后将抗体溶液转移至离心管或冻存管内；
称取5mg碱性磷酸酶溶解于1mL蒸馏水中，加入0.2mL新配的0.1M的NaIO 4溶液，2-8℃下避光反应30分钟，将上述溶液装入透析袋中，于1mM、pH4.4的醋酸钠缓冲液透析，4℃过夜，期间换透析液1次，透析后得醛化的碱性磷酸酶；
于醛化的碱性磷酸酶中加入20μL 0.2M、PH9.5的碳酸盐缓冲液， 然后立即加入2mg抗体，在2-8℃下避光反应2小时，再加0.1mL新配的4mg/mL的NaBH 4液，混匀，置于2-8℃下避光反应30分钟，最后将反应液液装入透析袋中，用0.01M、pH7.4的PBS缓冲液透析，2-8℃过夜，期间换液3次，取出反应液，加入等体积甘油，混匀，置于≤-15℃保存。
4)生物素标记的MGF抗体工作液以及碱性磷酸酶标记的MGF抗体工作液的制备
配制pH为7.5，浓度为0.05mol/L的Tris缓冲液，所述缓冲液含有质量百分含量为2wt％的牛血清白蛋白、0.1wt％的酪蛋白、60mg/L的鼠IgG、1wt％的氯化钠、1wt％的蔗糖、2wt％的小牛血清、1mmol/L的氯化镁、0.1mmol/L的氯化锌、0.5wt％的Tween-20、0.05wt％的proclin300；然后用该缓冲液配制抗体浓度为0.5mg/L的生物素标记的MGF抗体抗体工作液，以及抗体浓度为0.25mg/L碱性磷酸酶标记的MGF抗体工作液。
5)校准品和质控品工作液的配制
配制pH为7.4，浓度为0.1mol/L的N-(2-羟乙基)哌嗪-N′-(2-乙磺酸)(HEPES)缓冲液，所述缓冲液含有质量百分含量为1wt％的牛血清白蛋白、20wt％的人血清、1wt％的氯化钠、5wt％的乙二醇、0.1wt％的Tween-20、0.2wt％的proclin 300；然后用该缓冲液配制MGF校准品和质控品工作液，校准品共6个点，MGF的浓度分别为0pmol/L、0.8pmol/L、4pmol/L、16pmol/L、80pmol/L、200pmol/L，质控品分高中低三个浓度，MGF的浓度分别为4pmol/L、16pmol/L、80pmol/L。
6)清洗液的配制
配制pH为7.5，浓度为0.2mol/L的Tris缓冲液，所述缓冲液含有质量百分含量为1wt％的Tween 20、10wt％的氯化钠、10wt％的proclin300。
7)化学发光底物液的配制
配制0.2mol/L 2-氨基-2-甲基-1-丙醇缓冲液作为底物液，所述缓冲液含有0.05wt％的3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐、0.04wt％的2,5-双(5-叔丁基-2-苯并恶唑基)噻吩、1mmol/L的氯化镁、0.1mmol/L的氯化锌、0.1wt％的Triton X-100、0.1wt％的proclin 300。
8)试剂分装及组装，将链霉亲和素偶联的磁性微粒工作液3.0ml/瓶、生物素标记的MGF抗体工作液12ml/瓶、碱性磷酸酶标记的MGF抗体工作液12ml/瓶、校准品/质控品工作液1.0ml/瓶分装后，组装在一起，保存于2-8℃，将清洗液500ml/瓶、化学发光底物液500ml/瓶单独包装，保存于20℃-25℃。
实施例2 检测力生长因子和/或其E肽的化学发光试剂盒的制法
1)链霉亲和素偶联的磁性微粒工作液的制备
将链霉亲和素偶联的磁微粒悬浮液，磁分离去除上清，用pH为6.8，浓度为0.2mol/L的HEPES缓冲液重悬至浓度为1mg/mL，所述缓冲液含有质量百分含量为2wt％的牛血清白蛋白、0.02wt％的Triton X-100、0.05％叠氮钠。
2)生物素标记的MGF抗体的制备
取1mg MGF羊单克隆抗体，加入适量PBS缓冲液(0.05M，pH7.0-7.6)调整抗体浓度至1mg/ml，并加入透析袋中进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后将抗体转移至离心管或冻存管内；
准确称取1mg N-羟基琥珀酰亚胺活化的生物素(NHS-Biotin)，加入适量水调整其浓度为2mg/ml，得NHS-Biotin水溶液；
将NHS-Biotin水溶液加入抗体中，使NHS-Biotin与抗体按照1:100的摩尔比在2-8℃旋转混匀反应2小时，得生物素标记的MGF抗体溶液；
将生物素标记的MGF抗体溶液转移至透析袋进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后收集生物素标记的MGF抗体至离心管或冻存管内，加入1/10体积含5wt％BSA的PBS-BSA缓冲液(0.01M，pH7.0-7.6)，混匀后再加入甘油，所加甘油体积为所收集标记抗体体积加PBS-BSA缓冲液的体积，混匀后置于≤-15℃保存备用。
3)碱性磷酸酶标记的MGF抗体的制备
取1mg MGF兔多克隆抗体，加入适量CBS缓冲液(0.05M，pH8.0-9.6)调整抗体浓度至1mg/ml，并加入透析袋中，进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后将抗体溶液转移至离心管或冻存管内；
称取2mg碱性磷酸酶溶解于1mL蒸馏水中，加入0.1mL新配的0.1M的NaIO 4溶液，2-8℃下避光反应20分钟，将上述溶液装入透析袋 中，于1mM、pH4.4的醋酸钠缓冲液透析，4℃过夜，期间换透析液1次，透析后得醛化的碱性磷酸酶；
于醛化的碱性磷酸酶中加入20μL 0.2M、PH9.0的碳酸盐缓冲液，然后立即加入0.5mg抗体，在2-8℃下避光反应1小时，再加0.1mL新配的1mg/mL的NaBH 4液，混匀，置于2-8℃下避光反应20分钟，最后将反应液液装入透析袋中，用0.01M、pH7.4的PBS缓冲液透析，2-8℃过夜，期间换液3次，取出反应液，加入等体积甘油，混匀，置于≤-15℃保存。
4)生物素标记的MGF抗体工作液以及碱性磷酸酶标记的MGF抗体工作液的制备
配制pH为6.0，浓度为0.2mol/L的磷酸盐缓冲液，所述缓冲液含有质量百分含量为5wt％的牛血清白蛋白、0.0.02wt％的酪蛋白、1mg/L的鼠IgG、5wt％的氯化钠、1wt％的蔗糖、2wt％的小牛血清、1wt％的Tween-20、5mmol/L的硫酸镁、0.05mmol/L的硫酸锌、0.05wt％的proclin 300；然后用该缓冲液配制浓度为0.5mg/L的生物素标记MGF抗体工作液，以及浓度为0.25mg/L碱性磷酸酶标记MGF抗体工作液。
5)校准品和质控品工作液的配制
配制pH为7.6，浓度为0.2mol/L的N-(2-羟乙基)哌嗪-N′-(2-乙磺酸)(HEPES)缓冲液，所述缓冲液含有质量百分含量为5wt％的牛血清白蛋白、10wt％的人血清、0.5wt％的氯化钠、20wt％的乙二醇、0.02wt％的Tween-20、0.5wt％的proclin 300；然后用该缓冲液配制MGF-Ct24E校准品和质控品工作液，校准品工作液共6个点，MGF-Ct24E的浓度 分别为0pmol/L、0.8pmol/L、4pmol/L、16pmol/L、80pmol/L、200pmol/L，质控品分高中低三个浓度，MGF-Ct24E的浓度分别为4pmol/L、16pmol/L、80pmol/L。
6)清洗液的配制
配制pH为7.6，浓度为2mol/L的磷酸盐缓冲液，所述缓冲液含有质量百分含量为10wt％的Tween 20、5wt％的氯化钠、15wt％的proclin 300。
7)化学发光底物液的配制
配制0.01mol/L二乙醇胺缓冲液作为底物液，所述缓冲液含有0.01wt％的3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐、0.02wt％的2,5-双(5-叔丁基-2-苯并恶唑基)噻吩、5mol/L的硫酸镁、0.05mol/L的硫酸锌、0.02wt％的Tween 20、0.05wt％的叠氮钠。
8)试剂分装及组装，将链霉亲和素偶联的磁性微粒工作液3.0ml/瓶、生物素标记的MGF抗体工作液12ml/瓶、吖啶磺酰胺标记的MGF抗体工作液12ml/瓶、校准品/质控品工作液1.0ml/瓶分装后，组装在一起，保存于2-8℃，将清洗液500ml/瓶、化学发光底物液500ml/瓶单独包装，保存于20℃-25℃。
实施例3 检测力生长因子和/或其E肽的化学发光试剂盒的制法
1)链霉亲和素偶联的磁性微粒工作液的制备
将链霉亲和素偶联的磁微粒悬浮液，磁分离去除上清，用pH为7.6，浓度为0.01mol/L的磷酸盐缓冲液重悬至浓度为0.1mg/mL，所述 缓冲液含有质量百分含量为0.05wt％的酪蛋白蛋白、1wt％的Brij35、0.5％proclin 300。
2)生物素标记的MGF-Ct24E抗体的制备
取1mg MGF-Ct24E羊单克隆抗体，加入适量PBS缓冲液(0.05M，pH7.0-7.6)调整抗体浓度至1mg/ml，并加入透析袋中进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后将抗体转移至离心管或冻存管内；
准确称取1mg N-羟基琥珀酰亚胺活化的生物素(NHS-Biotin)，加入适量水调整其浓度为2mg/ml，得NHS-Biotin水溶液；
将NHS-Biotin水溶液加入MGF-Ct24E羊单克隆抗体中，使NHS-Biotin与MGF-Ct24E羊单克隆抗体按照1:10的摩尔比在室温条件下旋转混匀反应0.5小时，得生物素标记的MGF-Ct24E抗体溶液；
将生物素标记的MGF-Ct24E抗体溶液转移至透析袋进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后收集生物素标记的MGF-Ct24E抗体至离心管或冻存管内，加入1/10体积含5wt％BSA的PBS-BSA缓冲液(0.01M，pH7.0-7.6)，混匀后再加入甘油，所加甘油体积为所收集标记抗体体积加PBS-BSA缓冲液的体积，混匀后置于≤-15℃保存备用。
3)碱性磷酸酶标记MGF-Ct24E抗体的制备
取1mg MGF-Ct24E鼠单克隆抗体Fab片段，加入适量CBS缓冲液(0.05M，pH8.0-9.6)调整抗体浓度至1mg/ml，并加入透析袋中，进行透析，每隔3-4小时换一次透析液，更换3-4次，透析后将抗体溶液 转移至离心管或冻存管内；
称取8mg碱性磷酸酶溶解于1mL蒸馏水中，加入0.1mL新配的0.5M的NaIO 4溶液，2-8℃下避光反应40分钟，将上述溶液装入透析袋中，于1mM、pH4.4的醋酸钠缓冲液透析，4℃过夜，期间换透析液1次，透析后得醛化的碱性磷酸酶；
于醛化的碱性磷酸酶中加入20μL 0.2M、PH为10.7的碳酸盐缓冲液，然后立即加入1.6mg抗体，在2-8℃下避光反应3小时，再加0.1mL新配的3.2mg/mL的NaBH 4液，混匀，置于2-8℃下避光反应40分钟，最后将反应液液装入透析袋中，用0.01M、pH7.4的PBS缓冲液透析，2-8℃过夜，期间换液3次，取出反应液，加入等体积甘油，混匀，置于≤-15℃保存。
4)生物素标记的MGF-Ct24E抗体工作液以及碱性磷酸酶标记的MGF-Ct24E抗体工作液的制备
配制pH为7.6，浓度为0.01mol/L的Tris缓冲液，所述缓冲液含有质量百分含量为0.5wt％的牛血清白蛋白、100mg/L的鼠IgG、0.5wt％的氯化钠、5wt％的蔗糖、0.05wt％的小牛血清、0.02wt％的平平加O-20、0.5mmol/L的硫酸镁、0.5mmol/L的氯化锌、0.5wt％的叠氮钠；然后用该缓冲液配制浓度为0.5mg/L的生物素标记MGF-Ct24E抗体工作液，以及浓度为0.25mg/L的碱性磷酸酶标记MGF-Ct24E抗体工作液。
5)校准品和质控品工作液的配制
配制pH为6.8，浓度为0.01mol/L的MES缓冲液，所述缓冲液含有 质量百分含量为0.5wt％的牛血清白蛋白、1wt％的酪蛋白、50wt％的人血清、3wt％的氯化钠、2wt％的乙二醇、1wt％的Triton X-100、0.05wt％的proclin 300；然后用该缓冲液配制MGF校准品和质控品工作液，校准品工作液共6个点，MGF的浓度分别为0pmol/L、0.8pmol/L、4pmol/L、16pmol/L、80pmol/L、200pmol/L，质控品分高中低三个浓度，MGF的浓度分别为4pmol/L、16pmol/L、80pmol/L。
6)清洗液的配制
配制pH为6.8，浓度为0.1mol/L的磷酸盐缓冲液，所述缓冲液含有质量百分含量为0.2wt％的Triton X-100、20wt％的氯化钠、0.5wt％的叠氮钠。
7)化学发光底物液的配制
配制0.05mol/L 2-氨基-2-甲基-1-丙醇缓冲液作为底物液，所述缓冲液含有0.02wt％的3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐、0.01wt％的2,5-双(5-叔丁基-2-苯并恶唑基)噻吩、0.5mmol/L的硫酸镁、0.5mmol/L的氯化锌、0.5wt％的Triton X-100、0.5wt％的Tween 20、0.25wt％的proclin 300、0.25wt％的叠氮钠。
8)试剂分装及组装，将链霉亲和素偶联的磁性微粒工作液3.0ml/瓶、生物素标记的MGF-Ct24E抗体工作液12ml/瓶、异鲁米诺标记的MGF-Ct24E抗体工作液12ml/瓶、校准品/质控品工作液1.0ml/瓶分装后，组装在一起，保存于2-8℃，将清洗液500ml/瓶、化学发光底物液500ml/瓶单独包装，保存于20℃-25℃。
实施例4 使用本申请的试剂盒检测MGF和/或MGF-Ct24E的方法以全自动化学发光免疫分析仪(access2)为检测仪器，将试剂盒装载到仪器上进行检测，步骤如下：
将样本(或校准品或质控品)、生物素标记的MGF和/或MGF-Ct24E抗体工作液和碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液加入到反应杯中，37℃孵育10分钟，形成抗体-抗原-抗体夹心复合物溶液；
于抗体-抗原-抗体夹心复合物溶液中加入链霉亲和素包被的磁性微粒工作液，37℃孵育10分钟，形成磁性复合物悬浮液；
将磁性复合物悬浮液置于磁场内，将清洗液稀释10-30倍后，洗涤所述磁性复合物；
向洗涤后的磁性复合物中先后注入化学发光底物液，检测其光子强度。
实施例5 本申请的试剂盒的性能评估
1)最低检测限(分析灵敏度)的测定：
使用实施例1的试剂盒，通过实施例4的检测方法，重复测定S0校准品(0pmol/L)20次，RLU值为：2029、2375、2513、2666、2786、2595、2702、2753、2653、2298、2352、2228、2222、2782、2171、2147、2692、2801、2979、2627，RLU平均值
Figure PCTCN2018104101-appb-000001
为2519，标准差(s)为269；再用同样的方法重复测定S1校准品(0.8pmol/L)2次，RLU值为：16997、16401；根据S0校准品与S1校准品之间的校准品浓度-RLU平均值进行两点回归拟合得出一次方程，将
Figure PCTCN2018104101-appb-000002
值(3057) 代入一次方程中，求出对应的浓度值即最低检测限，结果为0.031pmol/L。
采用上述同样的方法，使用实施例2的试剂盒得到的最低检测限为0.025pmol/L，使用实施例3的试剂盒得到的最低检测限为0.037pmol/L。
2)回收率(准确度)实验：
使用实施例1的试剂盒，将80pmol/L的高值校准品加入到0.8pmol/L低值校准品中，得回收样本，所加入的高值校准品与被加入的低值校准品的体积之比为1:9，通过实施例4的检测方法，对高值校准品、低值校准品、回收样本分别重复检测2次，得相应的RLU值，并计算得相应的浓度值和浓度平均值，检测结果见表1，按照下列公式计算回收率R，结果为105.2％。
Figure PCTCN2018104101-appb-000003
式中：R——回收率；
V 0——低值校准品的体积；
V——高值校准品的体积；
C——高值校准品加入后，回收样本的检测浓度；
C 0——低值校准品的检测浓度；
C S——高值校准品的检测浓度。
表1 回收率实验结果
Figure PCTCN2018104101-appb-000004
Figure PCTCN2018104101-appb-000005
采用上述同样的方法，使用实施例2的试剂盒得到的回收率为97.2％，使用实施例3的试剂盒得到的回收率为98.5％。
3)线性检测：
使用实施例1的试剂盒，通过实施例4的检测方法，将浓度分别为0.8pmol/L、4pmol/L、16pmol/L、80pmol/L、200pmol/L的校准品工作液，每一浓度水平重复检测3次，得相应的RLU值，并计算得相应的浓度值和浓度平均值，将浓度平均值和理论值用最小二乘法进行直线拟合，计算线性相关系数，结果相关系数R＝0.9997(结果见表2)。
表2 重复性实验结果
Figure PCTCN2018104101-appb-000006
采用上述同样的方法，使用实施例2的试剂盒得到的线性相关系 数为0.9992，使用实施例3的试剂盒得到的线性相关系数为0.9995。
4)重复性实验：
使用实施例1的试剂盒，通过实施例4的检测方法，重复测定浓度分别为4pmol/L、16pmol/L、80pmol/L的质控品工作液各10次，得相应的RLU值，并计算得相应的浓度值、浓度平均值
Figure PCTCN2018104101-appb-000007
和标准差(s)，按公式
Figure PCTCN2018104101-appb-000008
计算变异系数，三个浓度水平的质控品工作液对应的变异系数分别为3.5％、3.9％、3.2％(结果见表3)。
表3 重复性实验结果(单位：pmol/L)
Figure PCTCN2018104101-appb-000009
采用上述同样的方法，使用实施例2的试剂盒得三个浓度水平的质控品工作液对应的变异系数分别为3.6％、4.5％、5.1％，使用实施例3的试剂盒得三个浓度水平的质控品工作液对应的变异系数分别为3.3％、4.5％、3.8％。
以上述依据本申请的理想实施例为启示，通过上述的说明内容，相关工作人员完全可以在不偏离本项申请技术思想的范围内，进行多样的变更以及修改。本项申请的技术性范围并不局限于说明书上的内容，必须要根据权利要求范围来确定其技术性范围。

Claims (10)

  1. 一种检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，包括：链霉亲和素偶联的磁性微粒工作液，生物素标记的MGF和/或MGF-Ct24E抗体工作液，碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液，含3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐的化学发光底物液，清洗液。
  2. 根据权利要求1所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，所述MGF和/或MGF-Ct24E抗体为单克隆抗体、多克隆抗体、单克隆抗体Fab片段或多克隆抗体Fab片段。
  3. 根据权利要求1或2所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，所述链霉亲和素偶联的磁性微粒工作液由pH为6.8～7.6，浓度为0.01mol/L～0.2mol/L的磷酸盐缓冲液、Tris缓冲液、HEPES缓冲液、MOPSO缓冲液中的一种配制而成，所述缓冲液含有质量百分含量为0.05～2wt％的牛血清白蛋白和/或酪蛋白、0.02～1wt％的十二烷基聚乙二醇醚和/或聚乙二醇对异辛基苯基醚和/或聚氧乙烯失水山梨醇单月桂酸酯和/或月桂醇聚氧乙烯醚、0.05～0.5wt％的proclin 300和/或叠氮钠。
  4. 根据权利要求1-3任一项所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，所述生物素标记的MGF和/或MGF-Ct24E抗体以及碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液由pH为6.0～7.6，浓度为0.01mol/L～ 0.2mol/L的磷酸盐缓冲液、Tris缓冲液、HEPES缓冲液、MOPSO缓冲液中的一种配制而成，所述缓冲液含有质量百分含量为0.5～5wt％的牛血清白蛋白、1～100mg/L的鼠IgG、0.5～5wt％的氯化钠、1～5wt％的蔗糖、0.05～2wt％的小牛血清、0.02～1wt％的酪蛋白、0.02～1wt％的十二烷基聚乙二醇醚和/或聚乙二醇对异辛基苯基醚和/或聚氧乙烯失水山梨醇单月桂酸酯和/或月桂醇聚氧乙烯醚、0.5-5mmol/L的硫酸镁或氯化镁、0.05-0.5mmol/L的氯化锌或硫酸锌、0.05～0.5wt％的proclin 300和/或叠氮钠。
  5. 根据权利要求1-4任一项所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，所述检测力生长因子和/或其E肽的金刚烷化学发光试剂盒还包括MGF和/或MGF-Ct24E校准品工作液和/或质控品工作液，所述MGF和/或MGF-Ct24E校准品和/或质控品工作液由pH为6.0～7.6，浓度为0.01mol/L～0.2mol/L的磷酸盐缓冲液、Tris缓冲液、HEPES缓冲液、MES缓冲液中的一种配制而成，所述缓冲液中含有质量百分含量为0.5～5wt％的牛血清白蛋白、10～50wt％的人血清、0.5～3wt％的氯化钠、2～20wt％的乙二醇、0.02～1wt％的Brij35和/或Triton X-100和/或Tween 20和/或平平加O-20、0.05～0.5wt％的proclin 300和/或叠氮钠。
  6. 根据权利要求1-5任一项所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，所述清洗液为pH为6.8～7.6，浓度为0.1mol/L～2mol/L的磷酸盐缓冲液或Tris缓 冲液，所述缓冲液含有质量百分含量为0.2～10wt％的Triton X-100和/或Tween 20、5～20wt％的氯化钠、0.5～15wt％的proclin 300和/或叠氮钠。
  7. 根据权利要求1-6任一项所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒，其特征在于，所述化学发光底物液为0.01-0.2mol/L二乙醇胺缓冲液或2-氨基-2-甲基-1-丙醇缓冲液，所述缓冲液含有0.01-0.05wt％的3-(2-螺旋金刚烷)-4-甲氧基-4-(3-磷氧酰)-苯基-1,2-二氧环己烷二钠盐、0.01-0.04wt％的2,5-双(5-叔丁基-2-苯并恶唑基)噻吩、0.5-5mmol/L的硫酸镁或氯化镁、0.05-0.5mmol/L的氯化锌或硫酸锌、0.02～1wt％的Triton X-100和/或Tween 20、0.05～0.5wt％的proclin 300和/或叠氮钠。
  8. 一种检测力生长因子、其E肽的金刚烷化学发光试剂盒的制法，其特征在于，包括：链霉亲和素偶联的磁性微粒工作液的制备，生物素标记的MGF和/或MGF-Ct24E抗体工作液的制备，碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体工作液的制备，清洗液的配制，化学发光底物液的配制，将上述制备的试剂进行分装及组装。
  9. 根据权利要求8所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒的制法，其特征在于，所述生物素标记的MGF和/或MGF-Ct24E抗体的制备方法为：将N-羟基琥珀酰亚胺活化的生物素与MGF和/或MGF-Ct24E抗体按照1:10-100的摩尔比在2-8℃或室温条件下旋转混匀反应0.5-2小时，透析除去多余的生物素，得生物素标记的MGF和/或MGF-Ct24E抗体。
  10. 根据权利要求8或9所述的检测力生长因子、其E肽的金刚烷化学发光试剂盒的制法，其特征在于，碱性磷酸酶标记的MGF和/或MGF-Ct24E抗体的制备方法为：
    于碱性磷酸酶水溶液中加入NaIO 4溶液，使碱性磷酸酶与NaIO 4按2-8mg:0.01-0.05mmol的比例在2-8℃下避光反应20-40分钟，透析除去多余的NaIO 4，得醛化的碱性磷酸酶；
    将醛化的碱性磷酸酶与MGF和/或MGF-Ct24E抗体于PH为9.0-10.7的反应体系中，在2-8℃下避光反应1-3小时，再加NaBH 4溶液混匀，置于2-8℃下避光反应20-40分钟，所述MGF和/或MGF-Ct24E抗体、NaBH 4与碱性磷酸酶的质量比为1:0.2:1-5，最后将反应液透析除去多余醛化的碱性磷酸酶和NaBH 4，得碱性磷酸酶标记MGF和/或MGF-Ct24E抗体。
PCT/CN2018/104101 2018-03-27 2018-09-05 检测力生长因子、其e肽的金刚烷化学发光试剂盒、制法 WO2019184248A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810260050.1A CN108490168A (zh) 2018-03-27 2018-03-27 检测力生长因子、其e肽的金刚烷化学发光试剂盒、制法
CN201810260050.1 2018-03-27

Publications (1)

Publication Number Publication Date
WO2019184248A1 true WO2019184248A1 (zh) 2019-10-03

Family

ID=63316676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/104101 WO2019184248A1 (zh) 2018-03-27 2018-09-05 检测力生长因子、其e肽的金刚烷化学发光试剂盒、制法

Country Status (2)

Country Link
CN (1) CN108490168A (zh)
WO (1) WO2019184248A1 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111175515A (zh) * 2019-12-30 2020-05-19 上海奥普生物医药股份有限公司 一种血清淀粉样蛋白a和c反应蛋白的二合一质控物及其制备方法
CN111812330A (zh) * 2020-06-23 2020-10-23 江苏奥雅生物科技有限公司 一种用于d-二聚体检测的试剂盒
CN112730839A (zh) * 2021-01-20 2021-04-30 宁波海壹生物科技有限公司 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒
CN113686841A (zh) * 2021-09-01 2021-11-23 北京利德曼生化股份有限公司 定量检测甲状腺素结合力试剂盒及其制备方法、检测方法
CN113804883A (zh) * 2021-09-16 2021-12-17 北京利德曼生化股份有限公司 测定人骨源性碱性磷酸酶含量的磁微粒化学发光检测试剂盒
CN114295567A (zh) * 2021-12-30 2022-04-08 青岛汉唐生物科技有限公司 一种磷脂酶a2检测试剂盒及其制备方法
CN116990513A (zh) * 2023-09-26 2023-11-03 北京美联泰科生物技术有限公司 胃蛋白酶原1的化学发光检测方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212180B (zh) * 2018-10-19 2021-10-12 广东菲鹏生物有限公司 用于小分子抗原与碱性磷酸酶标记结合物的保存液及其制备方法
CN110297094A (zh) * 2019-07-01 2019-10-01 北京大学第一医院 检测afamin浓度的试剂盒、制备方法及测定afamin浓度的方法
CN111060695A (zh) * 2019-12-23 2020-04-24 江苏三联生物工程有限公司 检测抗lrp4抗体的电化学发光试剂盒及其制法
CN111521830B (zh) * 2020-04-27 2024-02-23 四川沃文特生物技术有限公司 一种bnp检测试剂盒及缓冲液、酶工作液和应用
CN112698023B (zh) * 2020-12-01 2023-12-15 三诺生物传感股份有限公司 一种碱性磷酸酶标记结合物的保存液及其制备方法
CN113358868A (zh) * 2021-05-24 2021-09-07 迪瑞医疗科技股份有限公司 精子顶体酶化学发光免疫检测试剂盒及其制备方法
CN114486865B (zh) * 2022-02-16 2022-11-18 杭州博岳生物技术有限公司 一种磁微粒保存液及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097764A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
CN101602794A (zh) * 2009-05-08 2009-12-16 北京科技大学 一种人mgf多肽及其抗体制备方法
CN102068688A (zh) * 2010-12-01 2011-05-25 重庆大学 力生长因子及其e肽在制备治疗骨质疏松或骨缺损的药物及材料中的应用
CN103513037A (zh) * 2013-08-09 2014-01-15 北京润诺思医疗科技有限公司 一种人胰岛素原化学发光免疫分析测定试剂盒及其制备方法
CN103941021A (zh) * 2014-05-09 2014-07-23 深圳市国赛生物技术有限公司 一种检测白细胞介素-6的试剂盒以及非诊断目的检测白细胞介素-6的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101363861A (zh) * 2007-08-06 2009-02-11 北京科美东雅生物技术有限公司 乙型肝炎病毒表面抗原化学发光免疫分析测定试剂盒及其制备方法
CN101713779B (zh) * 2009-12-22 2013-04-10 陕西北美基因股份有限公司 一种用亲和素/链亲和素磁性复合微粒对生物分子进行免疫学检测的方法
WO2011116432A1 (en) * 2010-03-26 2011-09-29 Bond University Ltd Methods and compositions for detecting banned substances
CN105651990A (zh) * 2015-12-30 2016-06-08 深圳市新产业生物医学工程股份有限公司 一种17α-羟孕酮的化学发光检测试剂盒及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097764A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
CN101602794A (zh) * 2009-05-08 2009-12-16 北京科技大学 一种人mgf多肽及其抗体制备方法
CN102068688A (zh) * 2010-12-01 2011-05-25 重庆大学 力生长因子及其e肽在制备治疗骨质疏松或骨缺损的药物及材料中的应用
CN103513037A (zh) * 2013-08-09 2014-01-15 北京润诺思医疗科技有限公司 一种人胰岛素原化学发光免疫分析测定试剂盒及其制备方法
CN103941021A (zh) * 2014-05-09 2014-07-23 深圳市国赛生物技术有限公司 一种检测白细胞介素-6的试剂盒以及非诊断目的检测白细胞介素-6的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAN, TONGBIN ET AL.: "The Changes in Skeletal Muscle Ultrastructure and MGF during and after Exhaustive Exercise in Rat", CHINESE JOURNAL OF SPORTS MEDICINE, vol. 31, no. 10, 31 October 2012 (2012-10-31), pages 869 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111175515A (zh) * 2019-12-30 2020-05-19 上海奥普生物医药股份有限公司 一种血清淀粉样蛋白a和c反应蛋白的二合一质控物及其制备方法
CN111175515B (zh) * 2019-12-30 2024-04-26 上海奥普生物医药股份有限公司 一种血清淀粉样蛋白a和c反应蛋白的二合一质控物及其制备方法
CN111812330A (zh) * 2020-06-23 2020-10-23 江苏奥雅生物科技有限公司 一种用于d-二聚体检测的试剂盒
CN112730839A (zh) * 2021-01-20 2021-04-30 宁波海壹生物科技有限公司 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒
CN112730839B (zh) * 2021-01-20 2024-01-30 宁波海尔施智造有限公司 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒
CN113686841A (zh) * 2021-09-01 2021-11-23 北京利德曼生化股份有限公司 定量检测甲状腺素结合力试剂盒及其制备方法、检测方法
CN113804883A (zh) * 2021-09-16 2021-12-17 北京利德曼生化股份有限公司 测定人骨源性碱性磷酸酶含量的磁微粒化学发光检测试剂盒
CN114295567A (zh) * 2021-12-30 2022-04-08 青岛汉唐生物科技有限公司 一种磷脂酶a2检测试剂盒及其制备方法
CN114295567B (zh) * 2021-12-30 2024-01-16 青岛汉唐生物科技有限公司 一种磷脂酶a2检测试剂盒及其制备方法
CN116990513A (zh) * 2023-09-26 2023-11-03 北京美联泰科生物技术有限公司 胃蛋白酶原1的化学发光检测方法
CN116990513B (zh) * 2023-09-26 2023-12-26 北京美联泰科生物技术有限公司 胃蛋白酶原1的化学发光检测方法

Also Published As

Publication number Publication date
CN108490168A (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
WO2019184248A1 (zh) 检测力生长因子、其e肽的金刚烷化学发光试剂盒、制法
WO2019184247A1 (zh) 检测力生长因子、其e肽的电化学发光试剂盒、制法
WO2019184249A1 (zh) 检测力生长因子、其e肽的直接化学发光试剂盒、制法
CN108700584B (zh) 标记复合物及其制备方法、试剂盒、应用和检测系统
EP0713096B1 (en) Immunoassay and kit for insulin-like growth factors
CN1623000A (zh) 多肽的定量分析方法
EP2092342B1 (en) A method for measuring plasma levels of pentraxin ptx3
JPS584782B2 (ja) チロキシンを定量するための放射免疫測定方法
JP2665503B2 (ja) インシュリン様成長因子の免疫分析を可能にするインシュリン様成長因子に対するモノクローナル抗体対
US9383373B2 (en) Methods for detecting fungal infection
CN109239368A (zh) 测定孕酮的方法及试剂盒
KR100210720B1 (ko) 수용액으로부터 중금속의 제거 및 분석을 위한 착화된 착화제 및 착화되지 않은 착화제에 대한 모노클로날 항체의 가변성 도메인의 폴리펩타이드
CN107043762A (zh) 一种提高辣根过氧化物酶保存稳定性的保存稳定剂及其保存方法
JP3490715B2 (ja) ヘモグロビン前進性グルコシル化終末産物の検出方法
CH685959A5 (de) Diagnostische Testpackung zur Bestimmung von Proteinen.
CN112710852B (zh) 一种gnp多肽的检测试剂盒及检测方法
US9551723B2 (en) Liquid reagent of thyroid hormone-immobilized carrier and use thereof
JP6690327B2 (ja) 尿中プロスタグランジンｅ主要代謝物の測定方法及びキット
CN111007259A (zh) 一种用于检测乙酰胆碱受体抗体（AchR-Ab）的电化学发光试剂盒的制备
Spiehler et al. Digoxin-like immunoreactive substance in postmortem blood of infants and children
CN111007261A (zh) 检测RyR-Ab的电化学发光试剂盒及其制法
JP2508915B2 (ja) 抗ＳＳＡ／ＲｏおよびＳＳＢ／Ｌａ抗体測定用抗原、その製造法ならびに抗ＳＳＡ／ＲｏおよびＳＳＢ／Ｌａ抗体の測定法
WO1995025794A1 (fr) Anticorps monoclonal anti-igf-i
JP4442340B2 (ja) 抗体、それを含有する吸着剤、および免疫測定試薬
US20160313356A1 (en) Methods and kits for detecting fungal infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18911333

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18911333

Country of ref document: EP

Kind code of ref document: A1